Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2020 2
2021 3
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Results by year
Filters applied: . Clear all
Page 1
Combination therapies for MPNSTs targeting RABL6A-RB1 signaling.
Kohlmeyer JL, Gordon DJ, Tanas MR, Dodd RD, Monga V, Darbro BW, Quelle DE. Kohlmeyer JL, et al. Oncotarget. 2021 Jan 5;12(1):10-14. doi: 10.18632/oncotarget.27862. eCollection 2021 Jan 5. Oncotarget. 2021. PMID: 33456709 Free PMC article.
Prognostic and therapeutic value of the Hippo pathway, RABL6A, and p53-MDM2 axes in sarcomas.
Desai C, Thomason J, Kohlmeyer JL, Reisetter AC, Ahirwar P, Jahanseir K, Leidinger M, Ofori-Amanfo G, Fritchie K, Velu SE, Breheny P, Quelle DE, Tanas MR. Desai C, et al. Among authors: kohlmeyer jl. Oncotarget. 2021 Apr 13;12(8):740-755. doi: 10.18632/oncotarget.27928. eCollection 2021 Apr 13. Oncotarget. 2021. PMID: 33889298 Free PMC article.
A porcine model of neurofibromatosis type 1 that mimics the human disease.
White KA, Swier VJ, Cain JT, Kohlmeyer JL, Meyerholz DK, Tanas MR, Uthoff J, Hammond E, Li H, Rohret FA, Goeken A, Chan CH, Leidinger MR, Umesalma S, Wallace MR, Dodd RD, Panzer K, Tang AH, Darbro BW, Moutal A, Cai S, Li W, Bellampalli SS, Khanna R, Rogers CS, Sieren JC, Quelle DE, Weimer JM. White KA, et al. Among authors: kohlmeyer jl. JCI Insight. 2018 Jun 21;3(12):e120402. doi: 10.1172/jci.insight.120402. eCollection 2018 Jun 21. JCI Insight. 2018. PMID: 29925695 Free PMC article.
Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo.
Kohlmeyer JL, Kaemmer CA, Lingo JJ, Voigt E, Leidinger MR, McGivney GR, Scherer A, Koppenhafer SL, Gordon DJ, Breheny P, Meyerholz DK, Tanas MR, Dodd RD, Quelle DE. Kohlmeyer JL, et al. Neurooncol Adv. 2022 Apr 9;4(1):vdac047. doi: 10.1093/noajnl/vdac047. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 35571990 Free PMC article.
RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth.
Umesalma S, Kaemmer CA, Kohlmeyer JL, Letney B, Schab AM, Reilly JA, Sheehy RM, Hagen J, Tiwari N, Zhan F, Leidinger MR, O'Dorisio TM, Dillon J, Merrill RA, Meyerholz DK, Perl AL, Brown BJ, Braun TA, Scott AT, Ginader T, Taghiyev AF, Zamba GK, Howe JR, Strack S, Bellizzi AM, Narla G, Darbro BW, Quelle FW, Quelle DE. Umesalma S, et al. Among authors: kohlmeyer jl. J Clin Invest. 2019 Mar 4;129(4):1641-1653. doi: 10.1172/JCI123049. eCollection 2019 Mar 4. J Clin Invest. 2019. PMID: 30721156 Free PMC article.
RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.
Kohlmeyer JL, Kaemmer CA, Pulliam C, Maharjan CK, Samayoa AM, Major HJ, Cornick KE, Knepper-Adrian V, Khanna R, Sieren JC, Leidinger MR, Meyerholz DK, Zamba KD, Weimer JM, Dodd RD, Darbro BW, Tanas MR, Quelle DE. Kohlmeyer JL, et al. Clin Cancer Res. 2020 Jun 15;26(12):2997-3011. doi: 10.1158/1078-0432.CCR-19-2706. Epub 2020 Feb 21. Clin Cancer Res. 2020. PMID: 32086342 Free PMC article.